Publications by authors named "Masao Osaki"
BMC Rheumatol
September 2020
Article Synopsis
- A 75-year-old man with undiagnosed sporadic inclusion body myositis (sIBM) experienced exacerbated symptoms after receiving pembrolizumab, an immune checkpoint inhibitor (ICI) therapy for cancer.
- His condition, characterized by progressive limb weakness and elevated creatine kinase (CK) levels, was confirmed through neurological examinations and muscle biopsy.
- The case highlights the need for screening for sIBM in patients with unexplained muscle weakness before starting ICI therapy, as this can help avoid complications and optimize treatment plans.
